Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Brief: Nyxoah Says U.S. Implants In DREAM IDE Study To Be Completed In Q1

Jan 10 (Reuters) - NYXOAH SA  NYXH.BR :
    * NYXOAH PROVIDES GENERAL CORPORATE UPDATE
    * IMPLANTED FIRST U.S. PATIENT IN DREAM IDE PIVOTAL STUDY IN
DECEMBER 2020; THERE ARE CURRENTLY 15 ACTIVE AND ENROLLING
PATIENT SITES IN U.S., WITH IMPLANTS EXPECTED TO BE COMPLETED IN
Q1 2022
    * SPRINT DISCUSSIONS WITH FDA REGARDING IDE STUDY FOR CCC
PATIENTS
IN U.S., WHICH NYXOAH HOPES TO COMMENCE IN SECOND HALF OF 2022
    * AS PROUD AND EXCITED AS WE ARE OF OUR SIGNIFICANT
ACCOMPLISHMENTS IN 2021, WE HAVE OUR SIGHTS SET MUCH HIGHER FOR
2022 - TAELMAN

Source text for Eikon:  ID:nGNX89bNqp 
Further company coverage:  NYXH.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))

Recent news on Nyxoah SA

See all news